The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 study of the SYK inhibitor fostamatinib and weekly paclitaxel for recurrent platinum-resistant ovarian cancer.
 
Stephanie Gaillard
Consulting or Advisory Role - Arcus Biosciences; AstraZeneca; Curio Science; Elevar Therapeutics; Elevar Therapeutics; GlaxoSmithKline; Immunogen; Novartis
Research Funding - AstraZeneca (Inst); Compugen (Inst); Genentech/Roche (Inst); Iovance Biotherapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - Sermonix Pharmaceuticals
 
Mary Wilkinson
No Relationships to Disclose
 
Lainie P. Martin
Consulting or Advisory Role - Elucida Oncology; Immunogen; Myriad Genetics; Sutro Biopharma
Research Funding - Agenus (Inst); AstraZeneca (Inst); Immunogen (Inst); Sutro bioPharma (Inst)
 
Amy Deery
No Relationships to Disclose
 
Amanda Langsdale
No Relationships to Disclose
 
Asnakech Bayable
No Relationships to Disclose
 
Marianna Zahurak
No Relationships to Disclose
 
Peng Huang
Patents, Royalties, Other Intellectual Property - artificial intelligent technique for lung cancer early diagnosis
 
Deborah Kay Armstrong
Consulting or Advisory Role - Johnson & Johnson/Janssen; Teon Therapeutics
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Eisai (Inst); Pfizer (Inst); Syndax (Inst)
Other Relationship - AstraZeneca; AstraZeneca; AstraZeneca
 
Ie-Ming Shih
No Relationships to Disclose
 
Tian-Li Wang
No Relationships to Disclose